RXI Pharma (RXII) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights
March 30, 2015 7:02 AM EDTMARLBOROUGH, Mass., March 30, 2015 /PRNewswire/ --Â RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology that address high-unmet medical needs, today reported its financial results for the fourth quarter and year ended December 31, 2014, and provided a business update.
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
"The past year has seen a steady growth and... More
